The goal of the SPARTA study is to learn if an investigational drug, called APL-101, can help patients with non-small cell lung cancer (NSCLC) or other advanced solid tumors with a genetic alteration in c-Met oncogene (such as amplification, fusion, or EXON 14 skipping mutation). Other advanced solid tumors include, but are not limited to, brain, head and neck, gastric, esophageal, biliary, pancreatic, or colorectal cancer.